<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106751</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL033</org_study_id>
    <nct_id>NCT05106751</nct_id>
  </id_info>
  <brief_title>A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial Folds</brief_title>
  <official_title>A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Performance and Safety of YVOIRE Classic plus on NLF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Study&#xD;
      to Evaluate the Performance and Safety of YVOIRE Classic plus Versus Comparator for Temporary&#xD;
      Correction of Nasolabial Folds.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change on the Nasolabial Fold Rating Scale (NLFRS) from baseline to Week24.</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Classic plus on Nasolabial Fold 24 weeks after treatment, the mean change from baseline to 24 weeks will be measured using 5-point Nasolabial Fold Rating Scale (NLFRS). NLFRS Grades are 0 (None/Minimal), 1 (Mild), 2 (Moderate), 3 (Severe), and 4 (Extreme).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate calculated using Nasolabial Fold Rating Scale (NLFRS) for Nasolabial fold at Week 24.</measure>
    <time_frame>24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Classic plus on Nasolabial fold 24 weeks after treatment, the responder rate defined as ≥ 1-point improvement on the 5-point Nasolabial Fold Rating Scale (NLFRS) from baseline to 24 weeks will be calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Correction of Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>YVOIRE Classic plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid dermal filler</intervention_name>
    <description>Hyaluronic acid dermal filler used for facial volume or wrinkle correction</description>
    <arm_group_label>Restylane Lidocaine</arm_group_label>
    <arm_group_label>YVOIRE Classic plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 21 years or above age.&#xD;
&#xD;
          -  2 or 3 of the 5-point (0-4) NLFRS (Nasolabial Fold Rating Scale).&#xD;
&#xD;
          -  Agree to use proper contraception as guided in the protocol.&#xD;
&#xD;
          -  Signed for Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have received permanent facial implants anywhere in the face or neck or planning&#xD;
             during the investigation.&#xD;
&#xD;
          -  have undergone facial plastic surgery of the lower face and nasolabial region within&#xD;
             12 weeks&#xD;
&#xD;
          -  have undergone semi-permanent filler in lower face&#xD;
&#xD;
          -  have undergone temporary dermal filler treatment in the lower two-thirds of face&#xD;
             within 12 months&#xD;
&#xD;
          -  Have undergone facial tissue augmentation or facial treatment with fat or botulinum&#xD;
             injections in the lower two-thirds of face&#xD;
&#xD;
          -  Have undergone mesotherapy or cosmetic procedures in face or neck within 6 months&#xD;
&#xD;
          -  have used any over-the-counter anti-wrinkle products or prescription anti-wrinkle&#xD;
             medicines for the nasolabial folds within 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dongyeop Shin</last_name>
    <phone>82-2-6987-4147</phone>
    <email>dongyeopshin@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LG Chem investigational site 01</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

